Get notified when GANX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, with limited cash and large accumulated deficit.
Gain Therapeutics launches at-the-market offering of up to $35.5M at $3.14 per share
Filed November 28, 2025 · ~2 min read
Key Changes
-
high
Gain Therapeutics is selling up to $35.5M of common stock through an at-the-market facility with Oppenheimer, at an assumed price of $3.14 per share.
The Offering verify on EDGAR → -
high
The company has substantial doubt about its ability to continue as a going concern, with $8.8M cash and $96.8M accumulated deficit as of Sept 30, 2025.
Risk Factors verify on EDGAR → -
high
New investors face immediate dilution of $2.30 per share, as net tangible book value after the offering is only $0.84 per share.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WS 10-Q) is open in full — no account needed.
Partner
Trade GANX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify